Format

Send to

Choose Destination
Am J Surg. 2012 Mar;203(3):405-9; discussion 409. doi: 10.1016/j.amjsurg.2011.09.010. Epub 2011 Dec 28.

Receptor changes in metachronous breast tumors--our experience of 10 years.

Author information

1
Department of Surgery, Providence Hospital and Medical Centers, Southfield, MI, USA. drjsbhullar@gmail.com

Abstract

INTRODUCTION:

Patients with primary breast cancer (PBC) are at 2 to 6 times higher risk for developing synchronous and metachronous breast cancer (MBC). The pathology and behavior of MBC still remains unclear.

METHODS:

We reviewed the charts of 108 women with MBC at our hospital over the past 10 years. Profile patterns of the estrogen receptor (ER), the progesterone receptor (PR), and Her2/neu receptors were explored.

RESULTS:

Of 33 patients with ER(+)/PR(+) in the primary tumor, 23 (70%) retained the status in MBC. Forty-five (92%) of 49 patients with ER(-)/PR(-) in the primary tumor remained the same in MBC. Most Her2(-) tumors (22/31, 71%) remained negative, but 50% (8/16) of Her2(+) tumors became negative.

CONCLUSIONS:

Most MBC retained the ER/PR expression patterns irrespective of the treatment for the primary tumor, thus suggesting a common origin. Because MBCs tend to be triple negative and thus more aggressive, early detection and close surveillance techniques must be devised.

PMID:
22206855
DOI:
10.1016/j.amjsurg.2011.09.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center